When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Eli Lilly & Co. will set up a S$42 million ($31 million) digital health innovation hub in Singapore, expanding its research ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

Conditions are getting a bit more challenging for the drugmaker.

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other S&P 500 stocks. As per AXA Investment Managers, the US dominated financial markets this ...

Eli Lilly (NYSE: LLY) stock tanked after the company reported third-quarter results on Wednesday, Oct. 30. The report it issued before the opening bell was more than a little problematic.

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...